2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5679 Improving BCMA CAR-T cell therapy for multiple myeloma through TGF-β resistance and inducible IL-18 production

Sandhya Rai, Shijing Wang, PhD2, Bin Sun, MD3, Xinyi Yang, PhD4, Tyce Kearl, MD, PhD5, Jing Dong, PhD6, Peiman Hematti, MD7, Siegfried Janz, MD8, Joseph Zenga, MD, MS9, Binod Dhakal, MD, MS10, Fumou Sun, PhD11
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, North Dakota State University, Fargo, North Dakota, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Introduction: BCMA-targeted CAR T-cell (CART) therapy has produced remarkable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, limited CART persistence, T-cell exhaustion, and relapse remain major obstacles to durable remission. Analysis of samples from patients who relapsed after BCMA CART therapy revealed persistent immunosuppressive programs, including TGF-β and PD-1 signaling, that may impair CART expansion and function. Our group at the Medical College of Wisconsin is conducting a phase 1 clinical trial (NCT05976555) evaluating a BCMA CART product engineered for TGF-β resistance through expression of dominant-negative TGF-β receptor II (dnTGFBR2). To further overcome immunosuppression within the MM microenvironment, we developed an enhanced CART platform combining CRISPR/Cas9-mediated PDCD1 disruption with targeted knock-in of activation-inducible, decoy-resistant IL-18 (DR18).

Methods: To guide CART design, we analyzed single-cell RNA-seq data from patients who relapsed following BCMA CART therapy. Early relapses were characterized by increased TGF-β signaling, enhanced T-cell exhaustion, and diminished IL-18-associated immune responses. Based on these findings, we engineered BCMA-dnTGFBR2 CARTs with CRISPR/Cas9-mediated PDCD1 disruption and targeted knock-in of an inducible DR18 cassette. CART phenotype, activation, exhaustion, and memory differentiation were assessed by flow cytometry following stimulation in the presence of TGF-β. Cytotoxicity against BCMA-positive H929 and MM1.S cells was measured by Incucyte live-cell imaging at effector-to-target ratios of 1:5 to 2:1. Long-term durability was evaluated during repeated CD3/CD28 stimulation with TGF-β (10 ng/mL) for up to 15 days, with viability, expansion, activation, and memory phenotype monitored every 3 days. Metabolic fitness was determined by Seahorse extracellular flux analysis. For in vivo studies, NSG mice bearing disseminated luciferase-expressing OPM2 tumors received UTD, BCMA-dnTGFBR2, BCMA-dnTGFBR2/PD1KO, BCMA-dnTGFBR2/DR18, or BCMA-dnTGFBR2/DR18/PD1KO CARTs. Tumor burden was monitored by bioluminescence imaging.

Results: Single-cell analysis demonstrated that T cells from patients with early relapses exhibited increased TGF-β signaling, activation of cellular stress-response pathways, and significantly higher expression of exhaustion-associated genes, including PDCD1, HAVCR2, LAG3, CTLA4, and TIGIT (P < 0.01). Early relapses were also associated with reduced TCR signaling and impaired Th1/Th2 differentiation, consistent with diminished IL-18-mediated immune responses.

Targeted monoallelic knock-in of DR18 into the PDCD1 locus enabled activation-dependent DR18 secretion under control of the endogenous PDCD1 promoter while abolishing PD-1 expression. The engineered CARTs exhibited potent cytotoxicity against BCMA-positive myeloma cells, achieving 81.4% target-cell lysis at a 2:1 effector-to-target ratio and exceeding parental BCMA-dnTGFBR2 CARTs. DR18 secretion increased following T-cell activation and was accompanied by sustained PD-1 suppression. During repeated stimulation with TGF-β, engineered CARTs maintained minimal PD-1 expression (1.17% versus 19.4% in parental CARTs), preserved high viability (96.6% through day 12), and retained functional activity through day 15. In contrast, parental BCMA-dnTGFBR2 CARTs showed marked loss of viability and function by day 12. Engineered cells also displayed increased central-memory and effector-memory populations together with enhanced glycolytic and mitochondrial fitness. In vivo, parental BCMA-dnTGFBR2 CARTs achieved only partial tumor control, while PD1KO CARTs produced improved but incomplete responses. BCMA-dnTGFBR2/DR18/PD1KO CARTs completely eradicated tumor by day 14, with no evidence of recurrence through day 42.

Conclusion: This study identifies relapse-associated immune programs as actionable therapeutic targets for improving BCMA CART therapy. Guided by transcriptomic analysis of patients with early relapses, we combined TGF-β resistance with PDCD1 disruption and activation-inducible DR18 production in a single armored CART platform. This strategy enhanced CART fitness, resistance to immunosuppression, persistence, and antimyeloma activity in vitro and in vivo. These findings support further development of this next-generation BCMA CART platform to improve response durability and reduce relapse in patients with RRMM.

Sandhya Rai: No relevant conflicts of interest to declare.